The primary objective of the prospective WSG-PRIMe study was to determine the impact of MammaPrint and BluePrint on systemic adjuvant chemotherapy decisions in hormone receptor (HR)-positive HER2-negative breast cancer in a representative German population. The gene discussed is ERBB2; the disease is breast cancer.